Global Lung Cancer Surgery Market | Rise at 5.9% CAGR | Medtronic, Ethicon, Intuitive Surgical Drive Precision Oncology Advancements
The global lung cancer surgery market is projected to grow from USD 1.6 billion in 2026 to USD 2.8 billion by 2036, exhibiting a CAGR of 5.9%. This growth is driven by increasing cancer incidence, adoption of minimally invasive and robotic-assisted surgical technologies, and advancements in precision oncology. Key players like Medtronic, Ethicon, and Intuitive Surgical are leading innovation in this evolving market, with segmentectomy being the leading application and hospitals dominating as end-users.
Boston Scientific stock hits 52-week low at 61.23 USD
Boston Scientific's stock has hit a 52-week low of $61.26, reflecting a 32% decline over the past year amidst market volatility. Despite the downturn, the company maintains a "GREAT" financial health score and is considered undervalued by InvestingPro, with analysts reiterating positive ratings and price targets ahead of its earnings report. Recent trial results for its Watchman FLX device, while showing a slightly higher ischemic stroke rate, were generally positive regarding safety and efficacy.
Leerink Reiterates Outperform on Boston Scientific (BSX) After CHAMPION-AF Readout
Leerink maintained an Outperform rating on Boston Scientific (BSX) following the CHAMPION-AF trial results, which met primary safety and efficacy endpoints for its WATCHMAN FLX device. While the data was not considered a "home run," it is expected to support incremental adoption and growth. Wells Fargo also maintained an Overweight rating, noting the results were "good, not great" due to a slightly higher ischemic stroke rate, but still validated the device as non-inferior to oral anticoagulants.
Automated Dispensing Machines Market Set to Boom Rapidly, Witnessing Strong Growth Through 2033 | Omnicell, BD, Swisslog, ScriptPro, Capsa Healthcare
Coherent Market Insights has released a comprehensive report on the Automated Dispensing Machines Market, forecasting strong growth through 2033. The report analyzes industry trends, competitive dynamics, and regional performance, featuring key players like Omnicell, BD, and Swisslog. It offers crucial insights for business leaders, investors, and strategists, covering market segmentation, research methodology, and strategic recommendations.
Johnson & Johnson brings next-gen Varipulse PFA catheter to Europe
Johnson & Johnson has launched its Varipulse Pro system in Europe following CE mark approval. This next-generation pulsed field ablation (PFA) catheter features a new pulse sequence designed to improve procedural efficiency and reinforce safety and effectiveness. The technology offers a lower temperature profile and faster ablation while maintaining integration with the Carto 3 mapping system for precise lesion delivery.
BOSTON SCIENTIFIC CORPORATION (BSX) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Boston Scientific Corporation Investors of Upcoming Deadline
Bernstein Liebhard LLP has issued a shareholder alert for Boston Scientific Corporation (NYSE: BSX) investors, reminding them of the upcoming May 4, 2026, deadline to file as a lead plaintiff in a securities fraud class action lawsuit. The lawsuit alleges that Boston Scientific made misrepresentations concerning its U.S. electrophysiology segment between July 23, 2025, and February 3, 2026. Investors who purchased shares during this period and suffered losses are encouraged to contact the firm to discuss their legal options.
Grewal Harpreet, Penumbra director, sells $32,822 in stock
Penumbra Inc. director Grewal Harpreet sold 100 shares of the company's common stock for $32,822 on April 2, 2026, after the stock surged 32% in the last six months. This transaction occurred under a Rule 10b5-1 trading plan, leaving Grewal with 8,719 shares. The sale follows recent robust financial performance for Penumbra, including strong Q4 2025 revenues, and news of its acquisition by Boston Scientific for $374 per share.
Stryker Corporation (SYK) stock price, news, quote and history
This article provides comprehensive financial information for Stryker Corporation (SYK), a medical technology company. It includes real-time stock data, historical performance, key financial metrics, earnings trends, and analyst insights. The company operates globally in medical devices, specializing in MedSurg, Neurotechnology, and Orthopaedics segments.
Boston Scientific Corp. stock: Down 35% but analysts see rebound potential
Despite a 35% drop in Boston Scientific Corp. (BSX) stock over the past six months, major analysts maintain "Buy" ratings, signaling a potential rebound for the medical device company. The stock's decline is attributed to growth concerns, legal issues, and a significant drop after Q4 2025 updates, but the company's strong Q4 performance, innovative portfolio in cardiology and electrophysiology, and high institutional ownership suggest underlying strength. Investors are advised to monitor upcoming Q1 earnings on April 22, 2026, and potential new product launches as key catalysts for recovery.
Kratos Defense & Security Solutions Inc (KTOS) Stock Price, Quote, News & History
Kratos Defense & Security Solutions Inc (KTOS) stock rose over 10% after Jefferies upgraded it from Hold to Buy with an $85 price target. The article provides current stock data, financial figures, analyst trends, and recent news regarding KTOS, including its role in drone warfare technology. It also lists key statistics, valuation metrics, and company debt information for potential investors.
AQST Investor Alert: AQUESTIVE THERAPEUTICS, INC.
Levi & Korsinsky, LLP has issued an investor alert for Aquestive Therapeutics, Inc. (NASDAQ: AQST) due to a pending securities class action lawsuit. The lawsuit alleges that Aquestive disseminated misleading statements regarding the regulatory approval timeline for its Anaphylm product, causing AQST shares to drop over 37% on January 9, 2026. Institutional investors with losses between June 16, 2025, and January 8, 2026, are encouraged to evaluate lead plaintiff opportunities.
8 Most Oversold Strong Buy-Rated Stocks to Invest In
This article highlights Maze Therapeutics, Inc. (NASDAQ: MAZE) as one of the most oversold strong buy-rated stocks. JPMorgan and H.C. Wainwright recently raised their price targets on MAZE following positive Phase 2 data for its drug MZE829, which showed promising efficacy in APOL1-mediated kidney disease. The company reported strong cash reserves and plans to advance MZE829 into a pivotal program, although the article suggests that some AI stocks might offer greater return potential.
Biodesix Announces AACR 2026 Posters and Presentations
Biodesix, Inc. will present seven abstracts, including two oral sessions, at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA, from April 17 - 22, 2026. The presentations highlight the company's expertise in blood- and tissue-based testing, covering novel proteomic and genomic approaches for oncology therapeutic selection, response monitoring, and Molecular Residual Disease (MRD) testing. This demonstrates Biodesix's comprehensive capabilities from basic research to clinical applications and pre-validated assays for partners, alongside advancements in their pipeline.
Orchestra BioMed : April 2026 Corporate Presentation
Orchestra BioMed's April 2026 Corporate Presentation highlights its vision to leverage partnerships for innovation and future profitability, focusing on two pivotal trial-stage programs: AVIM Therapy for hypertension and Virtue SAB for artery disease. The company is actively enrolling patients in global pivotal trials for both programs and emphasizes its partnership-driven commercialization strategy for substantial royalty-based revenue. Orchestra BioMed also outlines recent accomplishments, major catalysts expected in 2026-2027, and the significant market opportunities for its cardiovascular treatments.
Boston Scientific closes buyout of Valencia Technologies
Boston Scientific has finalized its acquisition of Valencia Technologies, a move that significantly strengthens its position in the competitive urge urinary incontinence market. The buyout gives Boston Scientific control of eCoin, a tibial nerve stimulator that will compete directly with Medtronic’s Altaviva. Analysts believe this market is largely under-penetrated, offering substantial growth opportunities for Boston Scientific as it leverages its existing urology commercial capabilities.
Hologic CEO Steve MacMillan To Retire
Hologic, Inc. announced that CEO Steve MacMillan will retire following the company's go-private transaction with Blackstone and TPG, expected to close around April 7, 2026. MacMillan's 12-plus year tenure saw significant growth in revenue, earnings per share, and stock price, along with the company's response to the COVID pandemic. The board and MacMillan expressed gratitude for his leadership, and a new CEO is expected to be announced upon the transaction's close.
Piper Sandler maintains Boston Scientific stock rating after device feedback
Piper Sandler reiterated its "overweight" rating on Boston Scientific (NYSE:BSX) and "neutral" on Medtronic PLC (NYSE:MDT) after an investor call with an electrophysiologist discussing cardiac device usage. Despite a slightly higher stroke risk with the Watchman device compared to oral anticoagulants, a high-volume electrophysiologist anticipates a 10-15% increase in annual implantations. The firm expects Watchman to contribute significantly to Boston Scientific's revenue growth, while expressing caution regarding Medtronic's other growth drivers.
BSX DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Boston Scientific (BSX) Investors of Securities Class Action Deadline on May 4, 2026
Faruqi & Faruqi, LLP is reminding Boston Scientific (BSX) investors of the May 4, 2026 deadline to seek the role of lead plaintiff in a federal securities class action. The lawsuit alleges that Boston Scientific and its executives made misleading statements regarding its U.S. EP segment, failing to disclose that its growth rate was unsustainable. This alleged misrepresentation led to an unexpected net income miss and underwhelming guidance for fiscal 2026, causing Boston Scientific's stock price to fall significantly on February 4, 2026.
Will Telix (ASX:TLX) Board Refresh Subtly Recast Its Governance And Growth Balancing Act?
Telix Pharmaceuticals (ASX:TLX) is set to appoint David Gill as a Non-Executive Director on May 11, 2026, with plans for him to eventually succeed Dr. Mark Nelson as Chair. This board refresh is anticipated to subtly influence the company's balance between growth ambitions and governance, especially given its dual-listed status and significant reinvestment in R&D. While immediate drivers are unchanged, the appointment is expected to impact how Telix manages its pipeline assets and future product launches, such as TLX101-Px (Pixclara).
Nike, Boston Scientific, And Sysco Are Among Top 10 Large Cap Losers Last Week (March 30-April 2): Are the Others in Your Portfolio?
The article identifies the top 10 large-cap losers from the trading week of March 30 to April 2, a shortened week due to the Good Friday holiday. Nike, Boston Scientific, and Sysco were among those listed, with their declines attributed to factors like disappointing financial results, acquisition announcements, analyst downgrades, and clinical trial data.
Value Stock Risks: Analyst Concerns on 3 Companies in 2026 - News and Statistics
StockStory's analysis highlights three value stocks—Zimmer Biomet, Renasant, and Eastern Bankshares—as potentially risky investments for 2026 due to concerns over future performance despite current valuations. Zimmer Biomet faces issues with below-peer revenue growth and low returns on capital. Renasant shows slow revenue growth and declining earnings per share, while Eastern Bankshares struggles with credit quality and low return on equity.
BSX Stockholders Have Opportunity to Lead Boston Scientific Corporation Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!
Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Boston Scientific Corporation (NYSE: BSX) alleging federal securities law violations. The lawsuit claims that Boston Scientific made materially false and misleading statements regarding its projected growth rate, particularly in its U.S. electrophysiology segment, and that the company was aware of adverse trends impacting this division. Investors who purchased Boston Scientific securities between July 23, 2025, and February 3, 2026, are encouraged to contact the firm to potentially serve as lead plaintiff by May 4, 2026.
JPMorgan Chase Boosts Stake in Beta Bionics
JPMorgan Chase has significantly increased its investment in Beta Bionics, a medical device company developing automated insulin delivery solutions for type 1 diabetes. This substantial boost in stake, over 3,200%, indicates growing confidence from Wall Street in Beta Bionics' potential to revolutionize diabetes care with its bionic pancreas technology. The investment firm now holds approximately 0.47% ownership in the Boston-based company.
Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX) and Alto Neuroscience, Inc. (ANRO)
This article highlights bullish analyst ratings for two healthcare companies: Boston Scientific (BSX) and Alto Neuroscience, Inc. (ANRO). Jefferies maintained a Buy rating on Boston Scientific with a $110.00 price target, and a Strong Buy consensus, while Alto Neuroscience also received a maintained Buy rating from Jefferies with a $35.00 price target, backed by a Strong Buy consensus. The article features insights from analysts Matthew Taylor and Andrew Tsai, noting their success rates and average returns.
Stryker Corporation (SYK) stock price, news, quote and history
This page provides a comprehensive overview of Stryker Corporation (SYK), a medical technology company. It includes current stock performance, historical data, financial metrics, and analyst insights. The company operates in MedSurg & Neurotechnology and Orthopaedics segments, offering a wide range of medical devices.
SI-BONE Inc stock: Why this medtech innovator could reshape spine surgery
SI-BONE Inc. is highlighted as a medical technology innovator focusing on sacroiliac (SI) joint dysfunction, an often-overlooked cause of chronic low back pain. The company's minimally invasive iFuse system for SI joint fusion offers a unique solution in the orthopedic market, positioning it as a leader in an underserved niche. Investors are urged to consider SI-BONE for its growth potential, strong market opportunity, and robust financial health, despite typical medtech investment risks.
What Abbott Laboratories (ABT)'s Oncology Test Integration Into OncoEMR Means For Shareholders
Abbott Laboratories recently integrated its Precision Oncology portfolio into Flatiron’s OncoEMR platform, allowing for digital ordering and result delivery of key oncology tests in over 1,600 U.S. community cancer centers. This integration is expected to enhance test utilization and streamline clinical workflows for Abbott (ABT), reinforcing its diagnostics segment. Despite potential benefits from this and other integrations like the Libre CGM data with Epic, the company still faces challenges such as margin pressure from tariffs and pricing in China and competitive pressures in diagnostics and diabetes care.
Boston Scientific Corp. Stock: Strong Growth in Medtech Amid Evolving Healthcare Demands
Boston Scientific Corp. (BSX) is highlighted as a leader in medical devices, particularly in cardiology and endoscopy, positioning it for strong growth in the evolving healthcare sector. The article emphasizes its robust R&D, strategic acquisitions, and focus on minimally invasive therapies that cater to long-term demographic trends like an aging population. North American investors are noted to favor the company due to its U.S.-centric revenue and consistent financial performance.
Catheter Precision seeks buyer for cardiac device business By Investing.com
Catheter Precision Inc. is seeking a buyer for its cardiac electrophysiology business, which includes FDA and CE Mark approved products LockeT and VIVO, to focus on its Flyte aviation platform. Despite the cardiac business having a high gross profit margin of 92.31%, the company's market capitalization is low, and its stock has significantly declined. Catheter Precision believes monetizing these assets will unlock value and allow it to be valued as a pure-play aviation business.
[EFFECT] BOSTON SCIENTIFIC CORP SEC Filing
This article announces an SEC Filing for BOSTON SCIENTIFIC CORP (BSX) with a neutral impact and sentiment. The filing, Form EFFECT, indicates the effectiveness of an S-4 filing as of April 1, 2026, at 9:00 A.M. It provides key company information, recent news, and other SEC filings related to Boston Scientific.
Crescent Biopharma Stock Surges 85%, With A 6-Day Winning Spree
Crescent Biopharma (CBIO) experienced an 85% surge in its stock price over a six-day winning streak, increasing its market cap by $270 million to $588 million. The article highlights the company's performance against the S&P 500 and presents key financial data for the last two fiscal years and quarters. It also suggests that while such streaks are attractive, investing requires thorough analysis, promoting Trefis's High Quality Portfolio for better returns with less risk.
Telix lines up next chair with board seat for biotech veteran David Gill
Telix (ASX/NASDAQ: TLX) has appointed David Gill as a Non-Executive Director, effective May 11, 2026, with the expectation that he will eventually succeed Dr. Mark Nelson as Chair. Gill brings over 35 years of experience in senior management and financial leadership within the biopharmaceutical and medical device sectors. His appointment is part of the company's board expansion and succession planning, aimed at strengthening governance and capital markets expertise, particularly given Telix's dual listing.
Boston Scientific Corp. stock outperforms competitors on strong trading day
Boston Scientific Corp. (BSX) saw its stock rally by 1.32% to $62.82 on Thursday, outperforming its competitors. This rise occurred during a mixed trading session where the S&P 500 Index increased by 0.11% and the Dow Jones Industrial Average fell by 0.13%. The positive performance ended a four-day losing streak for the company's stock.
INVESTOR DEADLINE: Boston Scientific Corporation (BSX)
Robbins Geller Rudman & Dowd LLP has announced a class action lawsuit against Boston Scientific Corporation (BSX) for alleged violations of the Securities Exchange Act of 1934. Investors who purchased common stock between July 23, 2025, and February 3, 2026, and suffered substantial losses, have until May 4, 2026, to seek appointment as lead plaintiff. The lawsuit claims Boston Scientific made misleading statements regarding revenue outlook and growth, and failed to disclose new competition impacting its Electrophysiology market share, leading to a significant stock price drop after unsatisfactory Q4 2025 financial results.
INVESTOR DEADLINE: Boston Scientific Corporation (BSX)
Robbins Geller Rudman & Dowd LLP announced an investor deadline of May 4, 2026, for a class action lawsuit against Boston Scientific Corporation (BSX). The lawsuit alleges that Boston Scientific made false and misleading statements regarding its revenue outlook and growth potential, and failed to disclose new competition impacting its U.S. Electrophysiology market share. This claim follows a more than 17% drop in stock price after the company's Q4 2025 financial results.
RBC Capital reiterates Boston Scientific stock rating on growth outlook
RBC Capital has reiterated an Outperform rating for Boston Scientific Corp. (NYSE:BSX) with a $115.00 price target, citing that near-term business shifts do not alter its long-term investment thesis. The firm anticipates strong growth drivers in various medical device segments and reasonable 2026 guidance. This outlook comes despite mixed investor reactions to recent CHAMPION-AF trial results, which analysts largely viewed positively for the company's Watchman heart implant.
At Harvard gala, QT Imaging CEO pushes earlier breast cancer detection
QT Imaging Holdings, Inc. CEO Dr. Raluca Dinu participated in the inaugural Shiftmakers Gala at Harvard University, highlighting the importance of early breast cancer detection. Dinu emphasized that their radiation-free imaging technology addresses the challenge of dense breast tissue, which often makes mammography alone insufficient for many women. The event, supported by Gloria Steinem, focused on women driving change, and QT Imaging's work will be featured in The Shift to further promote awareness.
BSX Price History for Boston Scientific Corp Stock
This Barchart.com page provides detailed price history for Boston Scientific Corp (BSX) stock, offering end-of-day prices, latest trades, and corporate actions such as dividends and splits. It highlights 52-week key points including high, low, and Fibonacci levels, along with data on new highs and lows over various periods ranging from 5 days to 20 years. Users can access extensive historical data, with Barchart Premier members having enhanced download capabilities.
Biopsy Devices Market to Reach US$ 6.85 Billion by 2033 at 10.15% CAGR; North America Leads with 42% Share - Key Players: Becton, Dickinson and Company, Hologic Inc., Boston Scientific Corporation
The global biopsy devices market is projected to reach US$ 6.85 billion by 2033, growing at a compound annual growth rate (CAGR) of 10.15% from US$ 2.68 billion in 2025. This growth is primarily driven by the increasing prevalence of cancer and other chronic diseases, alongside advancements in minimally invasive and image-guided biopsy technologies. North America is expected to maintain its leading position in the market, holding a 42% share, due to its advanced healthcare infrastructure and early adoption of innovative diagnostic tools.
Telix Appoints David Gill as Non-Executive Director
Telix Pharmaceuticals Limited has announced the appointment of David Gill as a Non-Executive Director, effective May 11, 2026, as part of its Board expansion and succession planning. Mr. Gill is a seasoned life sciences executive with extensive experience in general management and financial leadership, and is expected to succeed Dr. Mark Nelson as Chair in due course. His appointment is expected to provide valuable financial expertise and knowledge of U.S. capital markets to Telix's Board.
Johnson & Johnson Vision leader explains significance of latest IOL milestone
Johnson & Johnson Vision received FDA approval for its Tecnis PureSee intraocular lens (IOL), designed to provide patients with an extended depth of focus and clear vision with minimal visual disturbances. Peter Menziuso, Company Group Chair, Vision, Johnson & Johnson, emphasized that this IOL is the first and only EDOF IOL in the U.S. without a warning on loss of contrast sensitivity, offering a significant advancement in cataract care. He highlighted the importance of personalized options for patients and surgeons, expanding the Tecnis platform to address a wide range of visual needs.
Banque Pictet & Cie SA Has $25.83 Million Stake in Boston Scientific Corporation $BSX
Banque Pictet & Cie SA recently reduced its stake in Boston Scientific Corporation by 13.3%, now holding 270,871 shares valued at $25.83 million. The article highlights both positive catalysts, such as successful clinical trials and acquisitions, and negative sentiments like analyst downgrades, increased put-option volume, and securities-fraud class action filings. Despite these mixed signals, analysts maintain a "Moderate Buy" rating with an average target price of $104.36 for Boston Scientific.
Medtronic plc Stock: Navigating Transformation and Growth in MedTech Amid Analyst Shifts
Medtronic plc is undergoing a significant transformation, including a planned spinoff of its MiniMed diabetes business, and reported strong Q3 FY2026 results with revenue of $9.02 billion. The company is focused on high-margin therapies and boasts a robust dividend policy, approaching Dividend King status. While analysts show mixed views, with Barclays raising its target to $120, execution risks related to the spinoff and competitive pressures remain key areas for investors to monitor.
Assessing Abbott Laboratories (ABT) Valuation After New Flatiron Health Oncology Integration
Abbott Laboratories recently integrated its Precision Oncology testing portfolio with Flatiron Health's OncoEMR, enhancing its cancer diagnostics reach. Despite this expansion and other strategic moves, Abbott's share price performance has seen recent declines, though it appears undervalued by approximately 25% according to one narrative. The article suggests that while the company possesses strong fundamentals and growth potential, investors should consider potential risks like regulatory setbacks and competitive pressures before making investment decisions.
Artivion (AORT) details 2026 virtual meeting, director slate and Say on Pay
Artivion, Inc. (AORT) announced details for its virtual-only 2026 Annual Shareholder Meeting scheduled for May 12, 2026, at 9:00 a.m. ET. Shareholders as of March 16, 2026, will vote on the election of nine directors, the advisory "Say on Pay" resolution for executive compensation, and the ratification of Ernst & Young LLP as the independent auditor for 2026. The Board of Directors recommends voting in favor of all proposals, highlighting that non-employee directors are independent and executive compensation aligns with company performance.
Nisa Investment Advisors LLC Sells 18,182 Shares of Boston Scientific Corporation $BSX
Nisa Investment Advisors LLC reduced its stake in Boston Scientific Corporation by 4.6% in the fourth quarter, selling 18,182 shares and leaving 372,831 shares worth $35.55 million. This institutional selling comes amidst recent insider selling by CEO Michael F. Mahoney and a mix of positive clinical updates and negative analyst downgrades and class-action lawsuits affecting Boston Scientific's stock performance. Despite strong Q4 earnings, the company faces "mixed" analyst views and short-term event risks.
Is trending stock AZZ Inc. (AZZ) a buy now?
This article analyzes AZZ Inc. (AZZ) by examining its recent stock performance across different timeframes and comparing it to broader market trends. It highlights the stock's gains over the past week, month, quarter, and year, noting its outperformance relative to the S&P 500. The piece also mentions the company's Zacks Rank, which evaluates its earnings outlook.
Boston Scientific (BSX) Says CHAMPION-AF Trial Meets All Primary Endpoints
Boston Scientific (NYSE:BSX) announced that its CHAMPION-AF clinical trial for the WATCHMAN FLX device met all primary and secondary safety and efficacy endpoints, demonstrating a significant reduction in non-procedural bleeding risk for patients with non-valvular atrial fibrillation. This positive data led Goldman Sachs to reiterate a Buy rating, despite a lowered price target, while Evercore ISI added BSX to its "Tactical Outperform" list. The results were presented at the American College of Cardiology’s Annual Scientific Session and published in The New England Journal of Medicine.
Boston Scientific Corp. stock underperforms Wednesday when compared to competitors
Boston Scientific Corp. (BSX) stock fell by 1.20% on Wednesday, closing at $62.00, despite an overall positive trading session for the broader stock market. The S&P 500 Index (SPX) and the Dow Jones Industrial Average (DJIA) both saw gains. This marks the fourth consecutive day of losses for Boston Scientific Corp. shares.
Bronstein, Gewirtz & Grossman LLC Urges Aldeyra Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman LLC announces a class action lawsuit against Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) for alleged federal securities law violations. The lawsuit claims that Aldeyra made false and misleading statements regarding the inconsistent results of its reproxalap drug candidate's clinical trials. Investors who purchased Aldeyra securities between November 3, 2023, and March 16, 2026, are encouraged to join the class action, with a lead plaintiff deadline of May 29, 2026.
